<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02545985</url>
  </required_header>
  <id_info>
    <org_study_id>1.0</org_study_id>
    <nct_id>NCT02545985</nct_id>
  </id_info>
  <brief_title>First-in-man Sirolimus-eluting Prolim® Stent Registry</brief_title>
  <official_title>Novel Sirolimus-eluting Stent Prolim® With a Biodegradable Polymer in the All-comers Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Clinical Hospital of the Ministry of Internal Affairs and Administration, Warsaw, Poland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central Clinical Hospital of the Ministry of Internal Affairs and Administration, Warsaw, Poland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study was to assess the safety and the efficacy of the novel
      sirolimus-eluting Prolim® stent with a biodegradable polymer in the all-comers population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Investigators prospectively enrolled all patients with stable coronary artery disease or
      acute coronary syndrome, treated with Prolim® stent between January and December 2013 in two
      interventional cardiology centers in Poland. Angiographic control was planned at 12 months,
      in which 15% of patients (randomly chosen) underwent optical coherence tomography analysis.
      The primary end-point was the cumulative rate of cardiac death, myocardial infarction, and
      target lesion revascularization after 12 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint was the cumulative rate of major adverse cardiovascular events (MACE).</measure>
    <time_frame>12 months</time_frame>
    <description>consisting of cardiac death, myocardial infarction (MI) and clinically-driven target lesion revascularization (TLR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary endpoints included the rates of cardiac death, all-cause death, MI, TLR, TVR and stent thrombosis.</measure>
    <time_frame>12 moths</time_frame>
    <description>Secondary endpoints included the rates of cardiac death, all-cause death, MI, TLR, TVR and stent thrombosis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late lumen loss (LLL)</measure>
    <time_frame>12 moths</time_frame>
    <description>The value (in mm) of LLL assessed in qualitative coronary angiography (QCA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of covered struts assessed in optical coherence tomography (OCT)</measure>
    <time_frame>12 months</time_frame>
    <description>The percentage of covered struts assessed in OCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The neointima volume assessed in OCT</measure>
    <time_frame>12 months</time_frame>
    <description>The neointima volume (in mm3) assessed in OCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The device success rate</measure>
    <time_frame>intraoperative</time_frame>
    <description>The percentage of Prolim stents successfully implanted.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">204</enrollment>
  <condition>Sirolimus-eluting Stainless Steel Coronary Stent Prolim®</condition>
  <arm_group>
    <arm_group_label>Prolim stent implantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In patients with symptomatic coronary artery disease Prolim stent was implanted in coronary arteries</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Prolim stent deployment</intervention_name>
    <description>Prolim stent was implanted in patients who signed the informed consent and met the exclusion and inclusion criteria.</description>
    <arm_group_label>Prolim stent implantation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age ≥ 18 years old,

          -  stable coronary artery disease (SCAD) or acute coronary syndrome (unstable angina -
             UA, non-ST elevation myocardial infarction - NSTEMI or ST-elevation myocardial
             infarction - STEMI) and

          -  signed informed consent

        Exclusion Criteria:

          -  inability to take dual antiplatelet therapy for 12 months,

          -  left ventricular ejection fraction ≤ 30%,

          -  chronic total occlusions, and

          -  in-stent restenosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacek Bil, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Central Clinical Hospital of the Ministry of Internal Affairs</affiliation>
  </overall_official>
  <results_reference>
    <citation>Stettler C, Wandel S, Allemann S, Kastrati A, Morice MC, Schömig A, Pfisterer ME, Stone GW, Leon MB, de Lezo JS, Goy JJ, Park SJ, Sabaté M, Suttorp MJ, Kelbaek H, Spaulding C, Menichelli M, Vermeersch P, Dirksen MT, Cervinka P, Petronio AS, Nordmann AJ, Diem P, Meier B, Zwahlen M, Reichenbach S, Trelle S, Windecker S, Jüni P. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet. 2007 Sep 15;370(9591):937-48. Review.</citation>
    <PMID>17869634</PMID>
  </results_reference>
  <results_reference>
    <citation>Lavi S, Džavík V. Biodegradable Stent Platforms: Are We Heading in the Right Direction? Can J Cardiol. 2015 Aug;31(8):957-9. doi: 10.1016/j.cjca.2015.04.005. Epub 2015 Apr 14.</citation>
    <PMID>26095938</PMID>
  </results_reference>
  <results_reference>
    <citation>Nagoshi R, Shinke T, Otake H, Shite J, Matsumoto D, Kawamori H, Nakagawa M, Kozuki A, Hariki H, Inoue T, Ohsue T, Taniguchi Y, Iwasaki M, Nishio R, Hiranuma N, Konishi A, Kinutani H, Miyoshi N, Takaya T, Yamada S, Yasaka Y, Hayashi T, Yokoyama M, Kato H, Kadotani M, Ohnishi Y, Hirata K. Qualitative and quantitative assessment of stent restenosis by optical coherence tomography: comparison between drug-eluting and bare-metal stents. Circ J. 2013;77(3):652-60. Epub 2012 Dec 21.</citation>
    <PMID>23257388</PMID>
  </results_reference>
  <results_reference>
    <citation>Zhang Q, Qiu JP, Kirtane AJ, Zhu TQ, Zhang RY, Yang ZK, Hu J, Ding FH, DU R, Shen WF. Comparison of biodegradable polymer versus durable polymer sirolimus-eluting stenting in patients with acute st-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of the RESOLVE study. J Interv Cardiol. 2014 Apr;27(2):131-41. doi: 10.1111/joic.12102.</citation>
    <PMID>24697948</PMID>
  </results_reference>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 30, 2015</study_first_submitted>
  <study_first_submitted_qc>September 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2015</study_first_posted>
  <last_update_submitted>September 12, 2015</last_update_submitted>
  <last_update_submitted_qc>September 12, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 15, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Central Clinical Hospital of the Ministry of Internal Affairs and Administration, Warsaw, Poland</investigator_affiliation>
    <investigator_full_name>Jacek Bil</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>sirolimus</keyword>
  <keyword>coronary stent</keyword>
  <keyword>Prolim</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

